Cardio Diagnostics Holdings, Inc. (CDIOW) cash flow statement

CDIOWNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIO

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/30

$0.01+0.00 (0.00%)

Close on Oct 30, 2026Market cap $4.94MP/E –Yield –

Cardio Diagnostics Holdings, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	TTM FY 2025 2025-12-31	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31
Depreciation & Amortization	–	0.06	0.02	0.02	0.02	0.02	0.02
Stock-Based Compensation	0.11	0.10	2.59	2.63	2.68	3.79	1.28
Change in Accounts Receivable	0.01	0.01	-0.01	-0.01	-0.01	-0.02	0.00
Change in Accounts Payable	0.01	-0.12	-0.16	-0.55	-0.60	-0.52	-0.78
Operating Cash Flow	-5.73	-5.16	-4.99	-5.29	-5.17	-5.26	-5.67
Capital Expenditures	-0.19	-0.20	-0.21	-0.75	-0.74	–	-0.58
Investing Cash Flow	-0.42	-0.38	-0.40	-0.92	-0.93	-0.81	-0.79
Financing Cash Flow	3.43	14	12	4.56	2.36	0.92	3.63
Free Cash Flow	-5.91	-5.36	-5.21	-6.03	-5.91	–	-6.25
Interest Paid	0.01	0.02	0.02	0.02	0.02	0.03	0.03

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -43737.5%
Net margin: -43832.5%
Return on equity, FY2025: -78.6%

Financial strength

Current ratio: 17.15
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.0%

Valuation

P/E ratio: –
Price to sales: 333.38
Price to book: 0.67
Dividend yield: –